Conclusion: There has been an increase in administration of adjuvant chemotherapy to elderly patients with stage III colon cancer in The Netherlands since 1997. Survival of elderly patients with stage III colon cancer increased over time, at least partly due to stage migration. The large effect of adjuvant chemotherapy on survival in this study is likely to be associated with the selection of fitter patients for adjuvant treatment.
Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands 
introduction
Colon cancer is one of the most common cancer types in The Netherlands with >8000 new cases annually, 40% of whom aged >75 years [1] . It is the second most frequent cause of cancer death in The Netherlands with almost 4000 deaths in 2010, more than half being >75 years [2] .
Since the mid-1980s, improvement in colon cancer survival has been achieved among patients with lymph node-positive disease, in particular due to advances in adjuvant treatment [3, 4] and improved staging techniques which could have resulted in stage migration [5, 6] . The role of adjuvant treatment with 5-fluorouracil (5-FU)-based chemotherapy in younger stage III colon cancer patients is well established [7] , and in more recent years, 5-FU has often been combined with oxaliplatin [8] . For selected elderly patients with stage III colon cancer on 5-FU-based chemotherapy, a survival benefit was reported [9, 10] . Many elderly patients with stage III colon cancer do not receive adjuvant chemotherapy, because of comorbidity and fear of toxicity [11, 12, 13] .
According to the evidence-based national Dutch clinical practice guidelines, adjuvant chemotherapy is recommended. In case of high age and/or comorbidity, monotherapy can be chosen instead of combination chemotherapy (supplemental Table S1 , available at Annals of Oncology online) [14] . Previous population-based studies concluded that age was an important factor for adjuvant chemotherapy administration in patients with stage III colon cancer [12, 13] . Therefore, in this study, we evaluated to what extent Dutch patients with colon cancer aged 75 years and older received adjuvant chemotherapy in the period 1997-2009, as indicated in the national treatment guidelines, and the impact on overall and disease-specific survival.
methods data collection
Population-based data from the nationwide Netherlands Cancer Registry (NCR), which was started in 1989 and is maintained and hosted by the Comprehensive Cancer Centres, were used [1]. The NCR is based on notification of all newly diagnosed malignancies in The Netherlands by the automated pathological archive (PALGA). Additional sources are the national registry of hospital discharge diagnoses, which accounts for up to 8% of new cases [1] . Information on patient characteristics such as gender and date of birth, as well as tumour characteristics such as date of diagnosis, subsite (International Classification of Diseases for Oncology 3 [15] ), histology, stage [tumour-lymph node-metastasis (TNM) classification, according to the version that was used at the time of diagnosis; 16], grade, and primary treatment, are obtained routinely from the medical records about 9 months after diagnosis [1] . Adjuvant chemotherapy regimen is not considered in this study, since this is the focus of another study that will be published soon. The quality of the data is high, due to thorough training of the registrars and computerised consistency checks at regional and national levels. Completeness is estimated to be at least 95% [17] . Vital status of all patients was obtained actively on a regular basis from the integrated database of the municipal registry and from the database of deceased persons of the Central Bureau for Genealogy. For the current analyses, the criteria of the International Association of Cancer Registries for multiple primaries were applied [1] .
Cause of death, defined as the primary cause of death, was retrieved from Statistics Netherlands [2] . Since accuracy of cause of death is limited for colon and rectal cancer separately [18, 19] , misclassification of cause of death may have occurred: colorectal cancer (CRC) death was therefore investigated as one group.
For the present study, all patients aged 75 years or older with resected stage III (T any N + M 0 ) primary colon cancer (C18.0-C18.9) diagnosed in the period 1997-2009 in The Netherlands were included (n = 8051). Patients who did not undergo surgery for their colon tumour were not included (n = 137) i.e. 1.3% of those aged 75-79 years, 1.7% of those aged 80-84 years, and 2.4% of those aged ≥ 85 years. Age was divided into three subgroups for the analyses (75-79, 80-84, and ≥ 85 years). Tumour localisation was divided into anatomical subsites: proximal colon, consisting of the caecum, appendix, ascending colon, hepatic flexure, transverse colon, and splenic flexure (C18.0-C18.5); distal colon, consisting of the descending colon and sigmoid colon (C18.6-C18.7); and unknown or overlapping subsites of the colon (C18.8, C18.9). The study period was 
statistical analyses
Proportions of patients who received adjuvant chemotherapy were described per period of diagnosis and according to age, gender, tumour site, stage, differentiation grade, and region. Differences in administration of chemotherapy between subgroups were tested by means of a chi-square test and differences over time were tested by the Cochran-Armitage trend test.
Multivariable logistic regression analysis stratified according to age groups (75-79 years and ≥ 80 years) was conducted for the following determinants of chemotherapy administration: age, gender, subsite, stage, tumour grade, period of diagnosis, and region. Two types of survival were calculated: overall survival and disease-specific survival. For overall survival analyses, all patients who died during the study period were considered as an end point, independent of cause of death. For disease-specific survival, we used cause of death to calculate survival and only death due to CRC was used as an end point, whereas patients who died due to other causes were censored at the date of death. Therefore, overall survival was slightly lower compared with disease-specific survival. Death due to chemotherapy is considered as death due to CRC. Overall survival time was defined as the time from diagnosis to death or 1 February 2010 for patients who were still alive. Disease-specific survival was calculated for patients diagnosed between 1997 and 2007 and disease-specific survival time was defined as the time from diagnosis to death due to CRC or 1 January 2009 for those who were still alive. A log-rank test was carried out to compare survival proportions. A multivariable proportional hazards regression analysis was used to discriminate independent risk factors for death. In addition, crude 5-year survival stratified according to adjuvant chemotherapy administration was calculated for age and period of diagnosis and log-rank tests were carried out, since the effect of period of diagnosis and age differed between patients who received adjuvant chemotherapy and those who did not. Cause of death was described for all patients diagnosed with colon cancer between 1997 and 2007 (SAS System 9.2, SAS Institute, Cary, NC). P values < 0.05 were considered statistically significant.
results

adjuvant chemotherapy
The proportion of elderly patients with stage III colon cancer (n = 8051) receiving adjuvant chemotherapy increased over time from 12% in 1997-2000 to 23% in 2007-2009 (P trend < 0.0001) ( Table 1 ). Large differences were seen between age groups. Among patients aged 75-79 years, this proportion doubled from 22% in 1997-2000 to 44% in 2007-2009 (P trend < 0.0001). A much smaller proportion of patients aged 80-84 years received adjuvant chemotherapy; however, this proportion more than doubled from 4% in 1997-2000 to 10% in 2007-2009. Almost none of the patients ≥ 85 years received adjuvant chemotherapy. A large variation in the administration of adjuvant chemotherapy was found between regions, ranging from 15% to 28%, but differences decreased over time (Table 1) . After adjustments for all variables listed in Table 2 , stratified analysis showed that patients aged 75-79 years received adjuvant chemotherapy more often when the tumour had a more advanced stage or was diagnosed in a more recent period (Table 2) . Among patients aged ≥ 80 years, female patients were less likely to receive adjuvant chemotherapy, while those with a more advanced stage or diagnosed in a more recent period were more likely to receive adjuvant chemotherapy. Among patients aged 75-79 years, there were two geographic regions where patients were more likely to 2  438  22  23  31  33  28  3  651  10  13  15  20  15  4  1768  10  13  18  21  16  5  697  10  17  13  19  14  6  1252  15  20  19  24  19  7  860  11  11  16  22  15  8  1008  13  15  17  25  18 a Including the caecum, appendix, ascending colon, and hepatic flexure. b Including the descending colon and sigmoid.
*Chi-square between subgroups: P < 0.05; **P < 0.0001. NOS, not otherwise specified. 
survival
A significantly better overall survival was found for patients who received chemotherapy compared with those who did not receive chemotherapy, with a better survival for those aged 75-79 years compared with those aged 80-84 years. Among patients not receiving adjuvant chemotherapy, a comparable effect of age was seen with the youngest patients having a better survival compared with the elderly patients (supplemental Figure S1 , available at Annals of Oncology online). Increasing age, male gender, proximal tumour site, more advanced stage, poor tumour grade, and earlier period of diagnosis were associated with a worse 5-year crude survival. Chemotherapy was the strongest predictor for survival after adjustment for relevant patient and tumour factors [hazard ratio (HR) 0.5; 95% confidence interval (CI) 0.4-0.5] (Table 3 ). In addition, among elderly colon cancer patients aged ≥ 80 years, those with a more advanced tumour stage and those with a poor tumour grade had a higher risk of dying after adjustment for various factors. Patients diagnosed in a more recent period and those with a lower stage had a better survival. No significant differences in overall survival were Including the descending colon and sigmoid. **P < 0.0001; *P < 0.05. CI, confidence interval; OR, odds ratio. Table S2 , available at Annals of Oncology online). Five-year disease-specific survival for patients aged 75-80 years was 38%, versus 27% for patients aged 80-85 years and 17% for those ≥ 85 years (P < 0.0001) (Figure 1 ).
cause of death
CRC was the major cause of death for patients with colon cancer stage III, the proportion of patients dying from CRC being around 60%, decreasing from 61% in those 75-79 years to 56% for those ≥ 85 years. Unspecified cancers of the digestive tract were the cause of death for 7% of the patients, while 9% of the patients died due to other cancers. Diseases of the circulatory system caused around 10% of deaths, increasing from 9% in those 75-79 years to 13% in those ≥ 85 years (supplemental Table S3 , available at Annals of Oncology online). Furthermore, among patients who received adjuvant chemotherapy, CRC was the cause of death in 72% of patients, versus 60% for those who did not receive adjuvant chemotherapy. For this latter group of patients, cardiovascular diseases were more common causes of death compared with those receiving adjuvant chemotherapy (10 versus 5%); the same applies for respiratory diseases (3% versus 1%).
discussion
In this nationwide Dutch study, the proportion of stage III colon cancer patients aged 75 years and older who received adjuvant chemotherapy increased over time. Patients ≥ 80 years as well as female patients received adjuvant chemotherapy less frequently, with a large variation between geographic regions. Overall survival increased clearly over time, for both patients receiving and those not receiving adjuvant chemotherapy. However, receiving adjuvant chemotherapy was the strongest positive predictor of survival in this retrospective study, while older age negatively influenced survival as well as male gender, tumour size, and grade. Geographic region was not correlated with survival. Five-year disease-specific survival decreased by age from 38% for those aged 75-80 years to 17% for those aged ≥ 85 years. Among patients with colon cancer stage III who died, CRC was the cause of death in 60% of patients, while 40% of deaths were due to other causes including comorbidity.
The administration of adjuvant chemotherapy in stage III colon cancer patients < 75 years increased in The Netherlands from 19% in 1989-1993 to 79% in 2004-2006 [13] . However, this study as well as previous studies have shown that a lower proportion of elderly patients received adjuvant chemotherapy [11, 13, 20, 21, 22] . Several explanations have been discussed in literature: e.g. the presence of concomitant diseases, frailty, and patient preferences [23, 24] . A subset of patients is not eligible for adjuvant chemotherapy due to postoperative mortality and morbidity [25, 26] or a short life expectancy, often due to comorbidity [27, 28] .
In addition, the decision of the medical oncologist, which is based on clinical experience, plays a role in the choice for adjuvant chemotherapy [24] . An equal benefit was reported for selected elderly patients with stage III colon cancer on 5-FUbased chemotherapy [9, 10] , although the benefit of oxaliplatin containing chemotherapy for elderly patients was less clear and higher toxicity levels were reported [29, 30] .
We found an increase in adjuvant chemotherapy administration to elderly patients over time, which is in agreement with a previous nationwide population-based study in The Netherlands [13] . This might be due to increased awareness of the effect of adjuvant chemotherapy on survival and therefore a better selection of patients who are eligible for adjuvant chemotherapy.
The variation across regions underscores the influence of local practice patterns in determining the use of adjuvant chemotherapy. Medical oncologists generally follow guidelines recommending adjuvant chemotherapy for stage III colon cancer patients who are relatively young and healthy but are less convinced to follow recommendations for patients who are older and sicker [31] . In the earlier years of this study, regional guidelines were often opinion based since evidence for the optimal treatment of elderly patients was limited and therefore guidelines differed between regions. In some regions, adjuvant chemotherapy was not recommended for elderly patients at the beginning of the study period (e.g. region 4), while in another region (region 2), adjuvant chemotherapy was administered much more frequently. This changed after the introduction of national clinical practice guidelines at the beginning of the 21st century. We did not find significant survival differences between the regions. However, differences in adjuvant chemotherapy administration were relatively small and other factors such as age and stage, which were evenly distributed over the various regions, might be more important factors for survival. Adjuvant chemotherapy for elderly patients with colon cancer is reported as an independent prognostic factor in several other population-based studies [32, 33] . Due to the population-based nature of our data, we do not know to what extent this positive prognostic factor can be explained by selection of the 'fitter' patients for adjuvant chemotherapy or by other factors not included in our analysis such as socioeconomic status. This is supported by the smaller survival difference found in randomised trials, although these trials mainly included patients who are relatively fit [34] . In our study population of elderly colon cancer patients, age had an independent effect on survival, most likely (at least partly) due to comorbidity [28, 35] .
The considerable improvement in survival of elderly patients with stage III colon cancer can probably be attributed to stage migration, since evaluation of lymph nodes became more adequate in The Netherlands during the study period [36] and imaging techniques have been developed over time to detect smaller metastases, which would have remained undetected otherwise [5, 6] . This generally resulted in an improved survival for stage III patients, since the patients with the worst survival of stage II become stage III patients and the worst patients with stage III become stage IV patients. This effect is supported by our finding that survival improved over time in a model both with and without adjuvant chemotherapy, indicating that there is an independent effect of period of diagnosis for elderly patients with colon cancer. This supports the hypothesis that stage migration plays an important role in the improved survival for elderly patients with colon cancer stage III.
Since we found an effect of period of diagnosis, it is likely that the effect of adjuvant chemotherapy on overall survival is smaller in elderly patients with colon cancer than in younger patients. Therefore, we should be careful about recommending adjuvant chemotherapy for this patient population of often vulnerable elderly patients.
We used 5-year overall survival, since De Gramont et al. concluded that extended survival after recurrence reduced the association between treatment effects on 3-year disease-free survival and overall survival [37] . This indicated that a followup of at least 5 years is needed to demonstrate overall survival improvements [37] .
The 5-year disease-specific survival for stage III colon cancer patients was quite similar to the 5-year overall survival (38% versus 40% for patients aged 75-79 years), despite the fact that 40% of the patients died due to other causes. Death caused by unspecified cancer of the gastrointestinal tract might often be due to CRC too. The finding that patients who did not receive adjuvant chemotherapy died more often from non-CRC diseases indicated that this group might justifiably not have received adjuvant chemotherapy, especially since they died more often due to cardiovascular and respiratory diseases which are frequent comorbidities in colon cancer patients [38] .
Although adherence to clinical guidelines is generally considered a measure of quality of care, deviating from these national guidelines in case of an elderly patient does not necessarily indicate an inferior quality of care. The large proportion of elderly patients presenting with comorbidity, and the lack of evidence-based guidelines for this group, often call for pragmatic individualised treatment [28] . Besides, during the study period, a regional guideline did not recommend the administration of adjuvant chemotherapy to elderly patients. In view of the growing proportion of elderly patients with colon cancer, partly because of the rising incidence rate, but especially because of the ageing population, clinicians will more frequently face difficult decisions regarding adjuvant chemotherapy.
In conclusion, this study demonstrates an increase in adjuvant chemotherapy administration to elderly patients with stage III colon cancer in The Netherlands since 1997, with a marked age gradient and large geographic variation. Survival of elderly patients with stage III colon cancer increased over time, most likely due to stage migration caused by better diagnosis over time and increased use of adjuvant chemotherapy. The marked effect of adjuvant chemotherapy on survival might be caused by selection of the fitter patients without comorbidity and a good performance status, which should be investigated further.
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